A5039768299- Acute Lymphoblastic Leukemia research
- Acute Myeloid Leukemia Research
- Hematopoietic Stem Cell Transplantation
- Childhood Cancer Survivors' Quality of Life
- Neuroblastoma Research and Treatments
- Immune Cell Function and Interaction
- CAR-T cell therapy research
- Chronic Myeloid Leukemia Treatments
- Glioma Diagnosis and Treatment
- Neuroendocrine Tumor Research Advances
- Brain Metastases and Treatment
- Lymphoma Diagnosis and Treatment
- Immunodeficiency and Autoimmune Disorders
- Chronic Lymphocytic Leukemia Research
- Lung Cancer Research Studies
- Mesenchymal stem cell research
- Autoimmune and Inflammatory Disorders Research
- Hemoglobinopathies and Related Disorders
- Genomic variations and chromosomal abnormalities
- Renal and related cancers
- Cancer, Hypoxia, and Metabolism
- Parvovirus B19 Infection Studies
- Prenatal Screening and Diagnostics
- Cancer Genomics and Diagnostics
- T-cell and B-cell Immunology
Instituto Murciano de Investigación Biosanitaria
2019-2025
Hospital Universitario Virgen de la Arrixaca
2014-2024
Hospital Universitario Son Espases
2012-2024
Instituto de Salud Carlos III
2024
Marqués de Valdecilla University Hospital
2021
Biomedical Research Institute
2019
Universidad Autónoma de Madrid
2019
Hospital Universitario La Paz
2019
Santa Lucía University General Hospital
2015
Hospital Universitario Son Dureta
2008-2015
To analyze the simultaneous combination of all-trans retinoic acid (ATRA) and anthracycline monochemotherapy for children with acute promyelocytic leukemia (APL).Since November 1996, 66 (younger than 18 years) genetically proven APL received induction therapy ATRA idarubicin. Consolidation consisted three courses monochemotherapy. After 1999, patients intermediate high risk relapse consolidation slightly reinforced doses Maintenance low-dose mercaptopurine methotrexate.Thirty-nine girls...
Relapse remains a major challenge in the clinical management of acute myeloid leukemia (AML) and is driven by rare therapy-resistant stem cells (LSCs) that reside specific bone marrow niches. Hypoxia signaling maintains quiescent metabolically relaxed state, desensitizing them to chemotherapy. This suggests hypothesis hypoxia contributes chemoresistance AML-LSCs may represent therapeutic target sensitize Here, we identify HIF
We aimed at assessing the clinical significance of levels acute lymphoblastic leukemia (ALL) cells in samples cerebrospinal fluid (CSF) during therapy. studied 990 CSF from 108 patients, time diagnosis (108) and each intrathecal therapy (882). The proportions leukemic were assessed by flow cytometry (FCM). Patients with central nervous system (CNS) involvement (FCM+) showed predominantly a T-ALL, higher percentages known negative prognostic factors: high risk group, white blood cell counts,...
B cell acute lymphoblastic leukemia (B-ALL) is the most common childhood cancer, with cure rates of ∼80%. MLL-rearranged (MLLr) B-ALL (MLLr-B-ALL) has, however, an unfavorable prognosis therapy refractoriness and early relapse, therefore new therapeutic targets are needed for relapsed/refractory MLLr-B-ALL. MLLr leukemias characterized by specific expression chondroitin sulfate proteoglycan-4, also known as neuron-glial antigen-2 (NG2). NG2 was recently shown involved in invasiveness central...
Identifying additional genetic alterations associated with poor prognosis in acute lymphoblastic leukemia (ALL) is still a challenge. Aims: To characterize the presence of DNA copy number (CNAs) children and adults ALL by whole-genome oligonucleotide array (aCGH) analysis, to identify their associations clinical features outcome. Array-CGH was carried out 265 newly diagnosed ALLs (142 123 adults). The NimbleGen CGH 12x135K (Roche) used analyze gains losses. CNAs were analyzed GISTIC aCGHweb...
In B-cell precursor acute lymphoblastic leukaemia (B-ALL), the identification of additional genetic alterations associated with poor prognosis is still importance. We determined frequency and prognostic impact somatic mutations in children adult cases B-ALL treated Spanish PETHEMA SEHOP protocols.Mutational status hotspot regions TP53, JAK2, PAX5, LEF1, CRLF2 IL7R genes was by next-generation deep sequencing 340 patients (211 129 adults). The associations between mutation clinicopathological...
A total of 192 pediatric patients, median age 8.6 years, with high-risk hematological malignancies, underwent haploidentical stem cell transplantation (haplo-HSCT) using post-transplantation cyclophosphamide (PT-Cy), or ex vivo T cell-depleted (TCD) graft platforms, from January 1999 to December 2016 in 10 centers Spain. Some 41 patients received an unmanipulated followed by PT-Cy for graft-vs-host disease (GvHD) prophylaxis. 151 were transplanted CD3-depleted peripheral blood cells (PBSCs)...
CD19-directed chimeric antigen receptor (CAR) T cells have yielded impressive response rates in refractory/relapse B cell acute lymphoblastic leukemia (B-ALL); however, most patients ultimately relapse due to poor CAR persistence or resistance of either CD19+ CD19- B-ALL clones. CD22 is a pan-B marker whose expression maintained both and relapses. CD22-CAR been clinically used patients, although also occurs. engineered with tandem (Tan-CAR) containing single construct CD19 scFvs may be...
Diamond-Blackfan Anemia Syndrome (DBAS) is characterized by impaired erythropoiesis due to dysfunctional ribosome biogenesis and aberrant cellular signaling. Here, we investigate how ribosomal stress-induced activation of the NLRP1 inflammasome modulates erythroid differentiation in DBAS. We demonstrate that FDA/EMA-approved tyrosine kinase inhibitors (TKIs) effectively mitigate defective anemia syndrome inhibiting activation. Specifically, nilotinib enhances K562 cells through suppression...
Relapsed or refractory (R/R) B-cell acute lymphoblastic leukemia (B-ALL) remains a challenging disease with dismal prognosis. Despite the revolutionary impact of CD19-directed chimeric antigen receptor (CAR19)-T cell therapy, >50% patients relapse within year. Both cell-intrinsic factors favoring immune escape and poor CAR-T persistence contribute significantly to clinical failure. Moreover, expression checkpoint receptors (ICRs) their ligands complex bone marrow (BM) microenvironment...
Aplastic anemia is a life-threatening bone marrow failure disorder characterized by peripheral pancytopenia and hypoplasia. The majority of cases aplastic remain idiopathic, although hematopoietic stem cell deficiency impaired immune responses are hallmarks underlying the in this condition. Mesenchymal stem/stromal cells constitute an essential component microenvironment because their immunomodulatory properties ability to support hematopoiesis, they have been involved pathogenesis several...
Diffuse infiltrating low-grade gliomas include oligodendrogliomas and astrocytomas, account for about 5% of all primary brain tumors. Treatment strategies these in adults have recently changed. The 2016 World Health Organization (WHO) classification has updated the definition tumors to their molecular characterization, including presence isocitrate dehydrogenase (IDH) mutation 1p/19p codeletion. In this new classification, histologic subtype grade II-mixed oligoastrocytoma also been...
Background Although adoptive transfer of CD19-directed chimeric antigen receptor (CAR) T-cells (CD19-CAR T-cells) achieves high rates complete response in patients with B-cell acute lymphoblastic leukemia (B-ALL), relapse is common. Bone marrow (BM) mesenchymal stem/stromal cells (BM-MSC) are key components the hematopoietic niche and implicated B-ALL pathogenesis therapy resistance. MSC exert an immunosuppressive effect on T-cells; however, their impact CD19-CAR T-cell activity...